EIP Pharma
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
EIP Pharma was a US biopharma company developing neflamapimod, an oral small-molecule brain-penetrant inhibitor of p38MAP kinase alpha, for degenerative diseases of the brain. Led by CEO John Alam, the company advanced neflamapimod as a potential first-to-market disease-modifying therapy for dementia with Lewy bodies (DLB), with additional programs in Alzheimer's disease and stroke recovery. Its Phase 2b DLB study (RewinD-LB) was fully funded by a $21 million grant from the National Institute on Aging.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Phase 2b initiated
EIP Pharma initiated the Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies, funded by a $21 million NIA grant.
- Merger with Diffusion
On August 16, 2023, EIP Pharma completed its merger with Diffusion Pharmaceuticals; the combined company operates as CervoMed Inc. (NASDAQ: CRVO), focused on advancing neflamapimod.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.